Effects of two lipid lowering therapies on immune responses in hyperlipidemic subjects
Nenhuma Miniatura disponível
Data
2014-03-11
Autores
Moreira, Flavio Tocci [UNIFESP]
Ramos, Silvia Cristina [UNIFESP]
Monteiro, Andrea Moreira
Helfenstein, Tatiana [UNIFESP]
Gidlund, Magnus
Teixeira Damasceno, Nagila Raquel
Figueiredo Neto, Antonio Martins
Izar, Maria Cristina [UNIFESP]
Helfenstein Fonseca, Francisco Antonio [UNIFESP]
Orientadores
Tipo
Artigo
Título da Revista
ISSN da Revista
Título de Volume
Resumo
Aims: To compare the effects of two of the most effective lipid-lowering therapies with similar LDL-cholesterol reduction capacity on the innate and adaptive immune responses through the evaluation of autoantibodies anti-oxidized LDL (anti-oxLDL Abs) and electronegative LDL [LDL(-)] levels.Main methods: We performed a prospective, randomized, open label study, with parallel arms and blinded endpoints. One hundred and twelve subjects completed the study protocol and received rosuvastatin 40 mg or ezetimibe/simvastatin 10/40 mg for 12 weeks. Lipids, apolipoproteins, LDL(-), and anti-oxLDL Abs (IgG) were assayed at baseline and end of study.Key findings: Main clinical and laboratory characteristics were comparable at baseline. Lipid modifications were similar in both treatment arms, however, a significant raise in anti-oxLDL Abs levels was observed in subjects treated with rosuvastatin (p = 0.026 vs. baseline), but not in those receiving simvastatin/ezetimibe. (p = 0.233 vs. baseline), thus suggesting modulation of adaptive immunity by a potent statin. Titers of LDL(-) were not modified by the treatments.Significance: Considering atherosclerosis as an immune disease, this study adds new information, showing that under similar LDL-cholesterol reduction, the choice of lipid-lowering therapy can differently modulate adaptive immune responses. (c) 2014 Elsevier Inc. All rights reserved.
Descrição
Citação
Life Sciences. Oxford: Pergamon-Elsevier B.V., v. 98, n. 2, p. 83-87, 2014.